Synthesis and biological activity of Akt/PI3K inhibitors

被引：15
|
作者：
Redaelli, C. [1 ]
Granucci, F. [1 ]
De Gioia, L. [1 ]
Cipolla, L. [1 ]
机构：
[1] Univ Milan, Dept Biosci & Biotechnol, I-20126 Milan, Italy
来源：
MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2006年 / 6卷 / 10期
关键词：
kinases; Akt; PI3K; cancer; kinase inhibitors; allosteric inhibitors; phosphatidylinositol; phosphatidylinositol analogues;
D O I：
10.2174/138955706778560139
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Phosphatidylinositol 3-kinase (PI3K) and serine/threonine protein kinase B (PKB or Akt) pathways regulate important cellular processes and are related to a number of human pathologies, such as cancer. The development of kinase inhibitors, with particular attention to small molecule analogues of natural phosphoinositides for pathway interruption and therapeutic applications will be reviewed.
引用
收藏
页码：1127 / 1136
页数：10
相关论文
共 50 条
  • [31] The Synergistic Anti-colon Cancer Effect of Aurora A Inhibitors and AKT Inhibitors Through PI3K/AKT Pathway
    Sun, Cheng
    Qu, Zhen
    Liu, Weilin
    Qiu, Zhigang
    Lu, Yanfeng
    Sun, Zhenqing
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (01) : 87 - 93
  • [32] The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma
    Fulda, S.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (06) : 729 - 737
  • [33] Novel inhibitors of the PI3K family
    Carnero, Amancio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (09) : 1265 - 1277
  • [34] Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
    Markman, Ben
    Dienstmann, Rodrigo
    Tabernero, Josep
    ONCOTARGET, 2010, 1 (07) : 530 - 543
  • [35] Targeting PI3K/AKT/mTOR network for treatment of leukemia
    Jessika Bertacchini
    Nazanin Heidari
    Laura Mediani
    Silvano Capitani
    Mohammad Shahjahani
    Ahmad Ahmadzadeh
    Najmaldin Saki
    Cellular and Molecular Life Sciences, 2015, 72 : 2337 - 2347
  • [36] PI3K Pathway Inhibitors: Better Not Left Alone
    Markman, Ben
    Tao, Jessica J.
    Scaltriti, Maurizio
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (05) : 895 - 906
  • [37] PI3K/AKT signaling and systemic autoimmunity
    Patel, RK
    Mohan, C
    IMMUNOLOGIC RESEARCH, 2005, 31 (01) : 47 - 55
  • [38] PI3K/Akt signalling pathway and cancer
    Vara, JAF
    Casado, E
    de Castro, J
    Cejas, P
    Belda-Iniesta, C
    González-Barón, M
    CANCER TREATMENT REVIEWS, 2004, 30 (02) : 193 - 204
  • [39] PI3K/Akt and apoptosis: size matters
    Franke, TF
    Hornik, CP
    Segev, L
    Shostak, GA
    Sugimoto, C
    ONCOGENE, 2003, 22 (56) : 8983 - 8998
  • [40] The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
    Kawauchi, Kiyotaka
    Ogasawara, Toshie
    Yasuyama, Masako
    Otsuka, Kuniaki
    Yamada, Osamu
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (05) : 550 - 559
12345